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etection of lamivudine and adefovir resistance mutations
mong Filipino patients with chronic hepatitis B using line
robe assay
. Baclig ∗, M. Alvarez, V. Liles, W. Polido Jr., I.H. Cua, J. Bocobo, F.
atividad, J. Gopez-Cervantes
St. Luke’s Medical Center, Quezon City, Philippines
Background: Hepatitis B virus (HBV) mutations conveying
esistance to antivirals are a major health concern worldwide in
he treatment of chronic hepatitis B infection. The availability of a
ensitive assay that can detect emerging HBV antiviral resistance
utations is important for individualized monitoring of response
o standard of care treatment. The risk of developing lamivudine
LAM) resistance is 14% to 70% after 1 to 5 years of treatment,
hich is sufﬁciently high to justify HBV antiviral resistance muta-
ion testing. On the other hand, resistance to adefovir (ADV) is
low to emerge, ranging from 3% to 29% following 1 to 5 years of
reatment. Mutation analysis helps in decision-making for clinical
anagement of chronic HBV infection and molecular epidemio-
ogical studies as well. This study seeks to determine the presence
f LAM and ADV resistance mutations among Filipino patients
linically diagnosed with chronic hepatitis B from July 2008 to
ecember 2011.
Methods: A total of fourteen samples were examined for the
resence of antiviral resistance mutations using line probe assay,
NNO-LiPA HBV DR v2. There were 9 (64%) males and 5 (36%)
emales with ages ranging from 17 to 69 years old.
Results: Among the fourteen samples, 5 (36%) had wild-type, 4
28%) had HBV mutant strain DNA not detected, and 5 (36%) had
BV DNA mutations. Out of the 5 HBV DNA mutant strains, one or
0% had one-drug resistance mutation detected (rtA181T for ADV).
hreeor 60%had3-drug resistancemutationspatterndetected. The
rst patient had rtG173L for LAMcompensatorymutation, rtL180M
or LAM, and rtM204V for LAM. The second patient had rtL80I
or LAM compensatory mutation, rtL180M for LAM, and rtM204I
or LAM, telbivudine (TBV). The third patient had L180L/A181T
pcoming resistance for ADV, M204I upcoming resistance for LAM,
mtricitabine, TBV, and N236T upcoming resistance for ADV. The
emaining one or 20% had 4 drug-resistance mutations detected
rtA181T for ADV, rtL180M for LAM, rtM204V for LAM, and rtM204I
or LAM, TBV).
Conclusion: The most frequently encountered LAM-resistant
utant was rtM204V/I. Overall, the line probe assay provides a
seful tool for the detection of lamivudine and adefovir resistance
utations among HBV-infected Filipino patients.
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Bioinformaticspredictionof siRNAsaspotential antiviral agents
against dengue viruses
B.L. Barron ∗, P.M. Villegas-Rosales, E. Ortega-Soto
Escuela Nacional de Ciencias Biológicas, IPN, Mexico City, DF, Mexico
Background: Dengue viruses (DENV 1 -4) represent the major
emerging arthropod-borne viral infection in the world. Currently,
there is neither a speciﬁc treatment nor an approved or available
vaccine for these viral infections. The main problem for developing
dengue vaccines is their inability to provide simultaneous protec-
tion against the four distinct viral serotypes. For this reason, there
is a need to develop antiviral drugs for treating this disease. We
propose the use of RNA interference (siRNA), targeting highly con-
served regions among the four DENV serotypes to silence the viral
genomes.
Methods: To identify highly conserved regions in the genome
of the four DENV serotypes, a multiple alignment with Clustal
X program was carried out, using all DENV genome sequences
available at NCBI data base, previously depurated by discarding
identical genome sequences with the virtual hybridization pro-
gram. For the siRNAdesign, four serverswereused: InvitrogenRNAi
Designer, Dharmacon siRNADesign Center, QiagenDesign Tool and
Ambion, Inc. Prediction of the genome’s secondary structure for
each serotype was obtained with the RNA structure program.
Results: A total of 2,893 complete DENV genomes were down-
loaded and after depuration 220 genomes were left. The highly
conservedzoneamong the four serotypeswas found tobe located in
the region corresponding to the NS4b and NS5 proteins. A consen-
sus sequence from these regions was used to siRNA design. Three
siRNAs that met most of criteria proposed for RNA silencing were
chosen. One targets the genome region that codiﬁes for NS4b pro-
tein and the other two, the region for NS5protein. To assure that
the siRNAs were speciﬁc for the relevant genome region; we per-
formed a BLAST analysis against homo sapiens database. Prediction
of the genome’s secondary structure was used to demonstrate that
the predicted siRNAs were complementary to the target site in the
viral genome.
Conclusion: The predicted siRNAs hybridized in silico with the
viral mRNA forming double-chain structures, which are necessary
to activate the silencing system; therefore, these siRNAs will behttp://dx.doi.org/10.1016/j.ijid.2012.05.172
